A Multiple Ascending Dose Study to Evaluate Safety and Tolerability of BFKB8488A in Participants With Type 2 Diabetes Mellitus and Participants With Non-Alcoholic Fatty Liver Disease
- Conditions
- Diabetes Mellitus, Type 2Non-Alcoholic Fatty Liver Disease
- Interventions
- Other: Placebo
- Registration Number
- NCT03060538
- Lead Sponsor
- Genentech, Inc.
- Brief Summary
This is a Phase Ib, randomized, blinded, placebo-controlled, multiple ascending-dose study of the safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) effects of BFKB8488A in participants with Type 2 diabetes mellitus (T2DM) and participants with non-alcoholic fatty liver disease(NAFLD). A maximum of approximately 160 participants will be enrolled across multiple sites in the United States. Participants will be randomly assigned to receive study drug (active BFKB8488A or placebo). The study will consist of a screening period (up to 8 weeks), a 12-week treatment period, and a 6-week follow-up period. Participants may come to clinic for an optional pre-screening visit.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 154
For T2DM Cohort only:
- Body mass index (BMI) ≥ 27 kg/m2 and ≤ 40 kg/m2.
- A confirmed diagnosis of Type 2 diabetes ≥ 6 months at screening
- Current stable treatment (at least 3 months) for diabetes
- Hemoglobin A1c (HbA1c) ≥ 6.8% and ≤ 9.0%.
- For women of childbearing potential, agreement to remain abstinent or use reliable contraception during treatment period and for at least 42 days after last dose of study drug
- For men, agreement to remain abstinent or use reliable contraception and agree to refrain from donating sperm
- For NAFLD cohort only:
- BMI ≥ 25 kg/m2 and ≤ 40 kg/m2
- At screening, confirmed liver fat by ultrasound OR calculated Liver Fat ≥ 10% using variables from the NAFLD liver fat score
- Hepatic steatosis on magnetic resonance imaging (MRI; ≥ 10% average liver proton density fat fraction [PDFF]) prior to randomization.
- Pregnant, lactating, or intending to become pregnant within 42 days after the last dose of study drug is administered
- Suspected or confirmed diagnosis of Type 1 diabetes
- Significant cardiac disease
- Any psychiatric illness that increases the risk of participation in the study
- History of severe allergic, anaphylactic, or other hypersensitivity reactions, or severe systemic bacterial, fungal, or parasitic infections
- Poor peripheral venous access
- Received blood products within 2 months before dosing
- Donation or loss of blood within 30-56 days prior to study drug administration
- Positive for hepatitis C virus (HCV) antibody, hepatitis B surface antigen (HBsAg), or human immunodeficiency virus (HIV) antibody
- Liver enzymes greater than acceptable limits
- History of eating disorders or surgical procedures for weight loss
- Active participation in a structured weight loss or dietary program
- Treatment with investigational therapy or exposure to any biological therapy
- Illicit drug use, marijuana use, or alcohol abuse
- Current use of more than one pack of cigarettes a day or equivalent nicotine- containing products
- Any serious medical condition or abnormality in clinical laboratory tests
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Placebo Placebo Participants will receive BFKB8488A-matching placebo. Multiple Ascending Dose BFKB8488A BFKB8488A Participants will be randomized to receive BFKB8488A. When adequate safety data are available, a review will be done for all participants to make a dose-escalation or dose and/or regimen modification decision. This will be repeated for each cohort.
- Primary Outcome Measures
Name Time Method Percentage of Participants with Adverse Events (AE) Up to 18 weeks following first dose administration An adverse event is any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product, regardless of causal attribution.
- Secondary Outcome Measures
Name Time Method Serum BFKB8488A Concentration On multiple days during treatment period and follow-up (up to 18 weeks following first dose administration) Change from Baseline in Percentage of Participants with Anti-Therapeutic Antibodies (ATAs) On multiple days during treatment period and follow-up (up 18 weeks following first dose administration) Participants are considered to be ATA positive if they are ATA negative at baseline but develop an ATA response following study drug administration (treatment-induced ATA response), or if they are ATA positive at baseline and at least one post-baseline samples if above acceptable limits. The number and percentage of ATA-positive and ATA-negative participants will be summarized by treatment group.
Trial Locations
- Locations (18)
MD Clinical
🇺🇸Hallandale Beach, Florida, United States
MidWest Clinical Research
🇺🇸Overland Park, Kansas, United States
Premier Research Associate, Inc
🇺🇸Miami, Florida, United States
inVentiv Health Clinical
🇨🇦Montreal, Quebec, Canada
Diabetes Research Center
🇺🇸Tustin, California, United States
Pinnacle Research Group Cullman
🇺🇸Anniston, Alabama, United States
Agile Clinical Research Trials
🇺🇸Atlanta, Georgia, United States
Pinnacle Research Group; Llc, Central
🇺🇸Anniston, Alabama, United States
Southern California Research Center, Inc.
🇺🇸Coronado, California, United States
Stanford Health Care
🇺🇸Stanford, California, United States
Dallas Diabetes & Endocrine Center
🇺🇸Dallas, Texas, United States
Carolina Research Center at Jones Family Practice
🇺🇸Shelby, North Carolina, United States
Texas Clinical Research Institute, LLC
🇺🇸Arlington, Texas, United States
Clinical Trials of Texas Incorporated
🇺🇸San Antonio, Texas, United States
Northeast Clinical Research of San Antonio LLC
🇺🇸San Antonio, Texas, United States
Consano Clinical Research
🇺🇸Shavano Park, Texas, United States
Hassman Research Institute
🇺🇸Berlin, New Jersey, United States
New Orleans Center for Clinical Research
🇺🇸Knoxville, Tennessee, United States